申请人:Hoffmann-La Roche Inc.
公开号:US20130123512A1
公开(公告)日:2013-05-16
The present invention relates in part to a process for the preparation of a proline derivative of formula I
wherein,
R
1
is C
1-7
-alkyl or
wherein R
4
is selected from the group consisting of C
1-7
-alkyl, halogen-C
1-7
-alkyl and phenyl optionally substituted by halogen;
R
2
is halogen or halogen-C
1-7
-alkyl; and
R
3
is selected from the group consisting of hydrogen, halogen, halogen-C
1-7
-alkyl, C
1-7
-alkoxy, halogen-C
1-7
-alkoxy and a 5- or 6-membered heterocyclic ring containing one or two nitrogen atoms, said ring being optionally substituted by C
1-7
-alkyl or halogen.
The proline derivatives of the formula I are preferential inhibitors of the cysteine protease Cathepsin S and are therefore useful to treat metabolic diseases like diabetes, atherosclerosis, abdominal aortic aneurysm, peripheral arterial disease and diabetic nephropathy.
本发明部分涉及一种制备式I的脯氨酸衍生物的过程
其中,
R
1
为C
1-7
-烷基或
其中R
4
选自由C
1-7
-烷基、卤代C
1-7
-烷基和苯基(可选择地被卤素取代)的群组;
R
2
为卤素或卤代C
1-7
-烷基; 以及
R
3
选自由氢、卤素、卤代C
1-7
-烷基、C
1-7
-烷氧基、卤代C
1-7
-烷氧基和含有一个或两个氮原子的5-或6-成员杂环环,该环可选择地被C
1-7
-烷基或卤素取代。
式I的脯氨酸衍生物是优选的半胱氨酸蛋白酶S的抑制剂,因此可用于治疗代谢性疾病,如糖尿病、动脉粥样硬化、腹主动脉瘤、外周动脉疾病和糖尿病肾病。